Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/31/2025

ASCVD Risk Assessment for Intermediate‑Risk Adults with Stage 1 Hypertension

Risk Assessment Tools

  • The American College of Cardiology/American Heart Association (ACC/AHA) guidelines require the use of the Pooled Cohort Equations (PCE) to estimate 10‑year ASCVD risk in adults aged 40–75 years. [1][2]
  • The PCE calculation incorporates age, sex, race, total cholesterol, HDL‑cholesterol, systolic blood pressure, antihypertensive treatment status, diabetes status, and smoking status. 3

Impact of Individual Risk Factors

  • Age 55 years is a strong driver of ASCVD risk in the PCE, especially for men. [4][1]5
  • Male sex confers a higher baseline ASCVD risk than female sex at the same age. 5
  • Presence of stage 1 hypertension (clinic BP ≈ 140/90 mmHg) meets the ACC/AHA definition for stage 1 hypertension and raises ASCVD risk. [2][6]
  • Absence of diabetes (HbA1c ≈ 4.4 %) removes an automatic ≥10 % 10‑year risk classification. 6
  • Normal renal function excludes chronic kidney disease as a high‑risk condition. 5

Guideline Recommendations for Stage 1 Hypertension

  • The ACC/AHA advises that patients with stage 1 hypertension be stratified as either < 10 % or ≥ 10 % 10‑year ASCVD risk to guide treatment decisions. [1][2]
  • In a model example, a 55‑year‑old man with treated BP 130/80 mmHg, total cholesterol ≈ 210 mg/dL, and HDL ≈ 50 mg/dL has an estimated 10‑year ASCVD risk of ~6 % (MESA calculator). 4
  • Using untreated BP 140/90 mmHg in the same scenario raises the estimated risk into the 7.5–10 % range. 4

Expected Risk Category

  • Based solely on age, sex, and hypertension status, a 55‑year‑old man with stage 1 hypertension most likely falls into the intermediate‑risk category (≥ 7.5 % to < 20 % 10‑year ASCVD risk). [1][2]
  • Typical intermediate‑risk estimates for this profile range from 7.5 % to 15 % depending on lipid values. 4
  • The patient is unlikely to be low‑risk (< 5 %) given his age and hypertension, and unlikely to be high‑risk (≥ 20 %) without additional major risk factors such as diabetes, established CVD, or severe dyslipidemia. 5

Risk‑Enhancing Factors and Additional Testing

  • For intermediate‑risk individuals, the ACC/AHA recommends evaluating risk‑enhancing factors—including family history of premature ASCVD, metabolic‑syndrome components, chronic inflammatory conditions, and elevated biomarkers (hs‑CRP, Lp(a), apoB)—to refine treatment decisions. [1][2]5
  • When uncertainty remains after obtaining a lipid profile, coronary artery calcium (CAC) scoring is reasonable to guide statin therapy. [1][2]
  • A CAC score of 0 reclassifies risk downward to approximately 1.5–3 % 10‑year risk, whereas a CAC score ≥ 100 supports initiation of statin therapy. 4

Clinical Considerations: White‑Coat Effect

  • The white‑coat effect (clinic BP 140/90 mmHg vs. home BP ≤ 130/85 mmHg) should be accounted for, as home BP monitoring predicts cardiovascular outcomes more accurately than clinic measurements. 7
  • Consistently lower home BP readings may indicate borderline hypertension, potentially lowering the calculated ASCVD risk. 7

Practical Takeaway

  • The patient should be classified as intermediate risk; however, obtaining a lipid profile (and, if needed, CAC scoring) is essential for precise risk quantification and informed treatment decisions. [1][2]

ASCVD Risk Assessment and Management

Risk Categories and Assessment

  • The American College of Cardiology/American Heart Association (ACC/AHA) defines ASCVD risk categories as low risk (<10%), intermediate/medium risk (≥10%), and high risk (presence of established cardiovascular disease) 8, 9, 10
  • The ACC/AHA uses the Pooled Cohort Equations for adults 40-79 years of age to assess 10-year ASCVD risk 10
  • Risk factors included in the calculation are age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, treatment for hypertension, diabetes, and smoking status 11, 12
  • The European Society of Cardiology/European Society of Hypertension (ESC/ESH) uses a more granular approach, categorizing risk as low (<1% 10-year CVD mortality), moderate (1% to <5%), high (5% to <10%), and very high (≥10%) 9, 10

High-Risk Conditions

  • Established cardiovascular disease automatically places patients in the high-risk category 8, 9
  • Other high-risk conditions include type 1 or type 2 diabetes mellitus, grade 3 hypertension, chronic kidney disease stages 3-5, and age ≥65 years 9, 11

Risk Refinement and Reclassification

  • For borderline or intermediate-risk patients, additional risk-enhancing factors such as family history of premature ASCVD, chronic inflammatory conditions, and South Asian ancestry can help refine risk assessment 13
  • Coronary Artery Calcium (CAC) scoring can help guide treatment decisions for intermediate-risk patients or selected borderline-risk patients 13, 14

Clinical Implications

  • Risk stratification is important for treatment decisions in adults with stage 1 hypertension (SBP 130-139 mmHg or DBP 80-89 mmHg) 8, 10
  • The ACC/AHA recommends lifetime risk assessment rather than 10-year risk for adults <40 years of age 9, 11

REFERENCES